Actively Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Led by AstraZeneca · Updated on 2026-02-25
240
Participants Needed
94
Research Sites
237 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of Surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.
CONDITIONS
Official Title
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years old and above
- Histologically confirmed relapsed or refractory follicular lymphoma (Module 1) or large B-cell lymphoma (Module 2) after at least 2 prior lines of therapy
- ECOG performance status 0 to 2
- Locally confirmed CD-19 expression in lymphoma cells after progression from last CD19-directed therapy
- FDG-avid disease with at least one measurable nodal lesion (> 1.5 cm) or extranodal lesion (> 1.0 cm)
- Adequate hematological function: ANC 21000/mm3, platelets 275,000/mm3, hemoglobin 29 g/dL, with stable counts for at least 72 hours if transfusions or growth factors used
- Adequate liver function: total bilirubin <1.5x ULN, AST/ALT 2 3xULN or < 5 �D7 ULN if liver involved
- Adequate renal function: creatinine clearance 2 45 mL/min
- Adequate cardiac function: left ventricular ejection fraction (LVEF) 2 45% by echocardiogram or MUGA
You will not qualify if you...
- Diagnosis of chronic lymphocytic leukemia (CLL), Burkitt lymphoma, or Richter's transformation
- Active central nervous system (CNS) involvement by B-NHL
- Leukemic presentation of B-NHL
- History or presence of significant CNS disorders such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, neurodegenerative disorders including Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, or other severe mental illness
- Prior therapy with T-cell engager within 8 weeks, autologous hematopoietic stem cell transplantation (HSCT) within 12 weeks, CAR T-cell therapy within 6 months, or prior allogeneic HSCT within 24 weeks of first dose of Surovatamig
- Requirement for chronic immunosuppressive therapy
- Unresolved non-hematological adverse events 2 Grade 2 from prior therapies
- History of Grade 3 or higher cytokine release syndrome (CRS) or neurotoxicity from prior CAR T or T-cell engager therapy
- History of major cardiac abnormalities
- Pregnancy or breastfeeding if female
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 94 locations
1
Research Site
Phoenix, Arizona, United States, 85054
Not Yet Recruiting
2
Research Site
Duarte, California, United States, 91010
Actively Recruiting
3
Research Site
Jacksonville, Florida, United States, 32224
Not Yet Recruiting
4
Research Site
Tampa, Florida, United States, 33612
Actively Recruiting
5
Research Site
Chicago, Illinois, United States, 60637
Not Yet Recruiting
6
Research Site
Iowa City, Iowa, United States, 52242
Not Yet Recruiting
7
Research Site
Waukee, Iowa, United States, 50263
Actively Recruiting
8
Research Site
Overland Park, Kansas, United States, 66204
Withdrawn
9
Research Site
Rochester, Minnesota, United States, 55905
Actively Recruiting
10
Research Site
St Louis, Missouri, United States, 63110
Withdrawn
11
Research Site
New Brunswick, New Jersey, United States, 08901
Withdrawn
12
Research Site
New York, New York, United States, 10016
Actively Recruiting
13
Research Site
Charlotte, North Carolina, United States, 28204
Actively Recruiting
14
Research Site
Columbus, Ohio, United States, 43210
Actively Recruiting
15
Research Site
Portland, Oregon, United States, 97239
Actively Recruiting
16
Research Site
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
17
Research Site
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
18
Research Site
Pittsburgh, Pennsylvania, United States, 15232
Withdrawn
19
Research Site
Nashville, Tennessee, United States, 37203
Not Yet Recruiting
20
Research Site
Austin, Texas, United States, 78704
Not Yet Recruiting
21
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
22
Research Site
San Antonio, Texas, United States, 78229
Not Yet Recruiting
23
Research Site
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
24
Research Site
Heidelberg, Australia, 3084
Actively Recruiting
25
Research Site
Kogarah, Australia, NSW 2217
Actively Recruiting
26
Research Site
Macquarie University, Australia, 2109
Actively Recruiting
27
Research Site
Nedlands, Australia, 6009
Actively Recruiting
28
Research Site
Porto Alegre, Brazil, 90035903
Suspended
29
Research Site
São Paulo, Brazil, 01401-002
Actively Recruiting
30
Research Site
São Paulo, Brazil, 05652-900
Actively Recruiting
31
Research Site
Barrie, Ontario, Canada, L4M 6M2
Not Yet Recruiting
32
Research Site
Brampton, Ontario, Canada, L6R 3J7
Actively Recruiting
33
Research Site
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
34
Research Site
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
35
Research Site
Chengdu, China, 610041
Actively Recruiting
36
Research Site
Chengdu, China, 610072
Actively Recruiting
37
Research Site
Guangzhou, China, 510060
Actively Recruiting
38
Research Site
Nanchang, China, 330029
Actively Recruiting
39
Research Site
Nanjing, China, 210029
Actively Recruiting
40
Research Site
Nantong, China, 226001
Actively Recruiting
41
Research Site
Shandong, China
Actively Recruiting
42
Research Site
Shanghai, China, 200025
Not Yet Recruiting
43
Research Site
Shanghai, China, 200032
Actively Recruiting
44
Research Site
Tianjin, China, 300020
Actively Recruiting
45
Research Site
Zhengzhou, China, 450008
Actively Recruiting
46
Research Site
Aalborg, Denmark, 9100
Withdrawn
47
Research Site
Copenhagen, Denmark, 2100
Actively Recruiting
48
Research Site
Vejle, Denmark, 7100
Actively Recruiting
49
Research Site
Montpellier, France, 34295
Actively Recruiting
50
Research Site
Paris, France, 75010
Actively Recruiting
51
Research Site
Pierre-Bénite, France, 69495
Actively Recruiting
52
Research Site
Rouen, France, 76038
Actively Recruiting
53
Research Site
Berlin, Germany, 10967
Actively Recruiting
54
Research Site
Chemnitz, Germany, 9116
Not Yet Recruiting
55
Research Site
Essen, Germany, 45147
Not Yet Recruiting
56
Research Site
Jena, Germany, 07747
Actively Recruiting
57
Research Site
Würzburg, Germany, 97080
Actively Recruiting
58
Research Site
Hong Kong, Hong Kong, 999077
Actively Recruiting
59
Research Site
Shatin, Hong Kong, 00000
Not Yet Recruiting
60
Research Site
Alessandria, Italy, 15121
Actively Recruiting
61
Research Site
Bologna, Italy, 40138
Actively Recruiting
62
Research Site
Busto Arsizio, Italy, 21052
Actively Recruiting
63
Research Site
Milan, Italy, 20132
Actively Recruiting
64
Research Site
Milan, Italy, 20141
Actively Recruiting
65
Research Site
Roma, Italy, 161
Not Yet Recruiting
66
Research Site
Chiba, Japan, 260-8717
Actively Recruiting
67
Research Site
Kashiwa, Japan, 277-8577
Actively Recruiting
68
Research Site
Kōtoku, Japan, 135-8550
Actively Recruiting
69
Research Site
Kumamoto, Japan, 860-0008
Actively Recruiting
70
Research Site
Niigata, Japan, 951-8520
Actively Recruiting
71
Research Site
Okayama, Japan, 700-8558
Actively Recruiting
72
Research Site
Osaka, Japan, 541-8567
Actively Recruiting
73
Research Site
Yokohama, Japan, 241-8515
Actively Recruiting
74
Research Site
Seoul, South Korea, 03080
Actively Recruiting
75
Research Site
Seoul, South Korea, 06351
Actively Recruiting
76
Research Site
Seoul, South Korea, 06591
Actively Recruiting
77
Research Site
Seoul, South Korea, 3722
Actively Recruiting
78
Research Site
Seoul, South Korea, 5505
Actively Recruiting
79
Research Site
Barcelona, Spain, 08035
Actively Recruiting
80
Research Site
Madrid, Spain, 28040
Actively Recruiting
81
Research Site
Pozuelo de Alarcón, Spain, 28223
Actively Recruiting
82
Research Site
Gothenburg, Sweden, 41345
Actively Recruiting
83
Research Site
Stockholm, Sweden, 17176
Actively Recruiting
84
Research Site
Kaohsiung City, Taiwan, 80756
Withdrawn
85
Research Site
Kaohsiung City, Taiwan, 833401
Actively Recruiting
86
Research Site
Taichung, Taiwan, 404
Actively Recruiting
87
Research Site
Taichung, Taiwan, 40705
Actively Recruiting
88
Research Site
Tainan, Taiwan, 70403
Actively Recruiting
89
Research Site
Taipei, Taiwan, 106
Actively Recruiting
90
Research Site
London, United Kingdom, SE5 9RS
Actively Recruiting
91
Research Site
Manchester, United Kingdom, M20 4BX
Actively Recruiting
92
Research Site
Norwich, United Kingdom, NR4 7UY
Actively Recruiting
93
Research Site
Nottingham, United Kingdom, NG5 1PB
Actively Recruiting
94
Research Site
Plymouth, United Kingdom, PL6 8DH
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here